title: Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
abstract: A new series of nonpeptide angiotensin II (AII) receptor antagonists has been prepared. These N-(biphenylyl-methyl)imidazoles, e.g. 2-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloro-5- (hydroxymethyl)imidazole, differ from the previously reported N-(benzamidobenzyl)imidazoles and related compounds in that they produce a potent antihypertensive effect upon oral administration; the earlier series generally were active only when administered intravenously. It has been found that the acidic group at the 2'-position of the biphenyl is essential. Only ortho-substituted acids possess both high affinity for the AII receptor and good oral antihypertensive potency. The carboxylic acid group has been replaced with a variety of acidic isosteres, and the tetrazole ring has been found to be the most effective. The tetrazole derivative, DuP 753, is currently in development for the treatment of hypertension.
authors.affiliation: Medical Products Department, E. I. du Pont de Nemours & Company, Inc., Wilmington, Delaware 19880-0402.
authors.forename: D J
authors.initials: DJ
authors.lastname: Carini
authors.forename: J V
authors.initials: JV
authors.lastname: Duncia
authors.forename: P E
authors.initials: PE
authors.lastname: Aldrich
authors.forename: A T
authors.initials: AT
authors.lastname: Chiu
authors.forename: A L
authors.initials: AL
authors.lastname: Johnson
authors.forename: M E
authors.initials: ME
authors.lastname: Pierce
authors.forename: W A
authors.initials: WA
authors.lastname: Price
authors.forename: J B
authors.initials: JB
authors.lastname: Santella
authors.forename: G J
authors.initials: GJ
authors.lastname: Wells
authors.forename: R R
authors.initials: RR
authors.lastname: Wexler
mesh_terms: D000284:Administration, Oral; D000311:Adrenal Glands / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000138:chemical synthesis* / Q000378:metabolism / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D006973:Hypertension / Q000188:drug therapy; D007093:Imidazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000627:therapeutic use; D019808:Losartan; D008297:Male; D015394:Molecular Structure; D051381:Rats; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000378:metabolism; D013329:Structure-Activity Relationship; D013777:Tetrazoles / Q000138:chemical synthesis / Q000627:therapeutic use
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D019808:Losartan